Find an expert

I am a medicinal chemist and postdoctoral research fellow at the University of Queensland, Australia, where I obtained my BSc (Hons) with a major in organic chemistry in 2011. Following this, I worked at the Institute for Future Environments and later the Centre for Tropical Crops and Biocommodities at QUT, where I gained experience in analytical chemistry, as well as molecular biology and genetics. In 2015, I returned to UQ to begin my PhD in the design and synthesis of novel antifungals targeting invasive infection under the supervision of Prof. Craig Williams and Prof. Luke Guddat, which I completed in 2019. My combined experience in synthetic chemistry - particularly in the synthesis of heterocyclic small molecules - and molecular biology has since led to my current position at UQ under the supervision of Prof. Avril Robertson, where my focus is once again on the design and synthesis of novel antifungals. Broadly, my research interests lie in the pursuit of drug design and development campaigns addressing difficult or under-researched clinical concerns, and in particular, the use of novel bioisosteric approaches to improve drugability and drug efficacy.

More recently, I have developed an interest in Australian mushroom species. Very little recorded knowledge on our endemic mushrooms species exists. My research in this space seeks to characterise the genetic and molecular features of Australian wood rot mushrooms, which are critical players in maintaining and restoring the health of our unique forests ecosystems. With this information we aim to better understand our fungal biodiversity and the ecological roles they play, and to explore their potential uses in several industries. We are also investigating the biological activity of extracts and molecules derived from these mushrooms against models of human diseases, such as Alzheimer's, cancer, and drug-resistant microbial infections.

After completing my undergraduate and postgraduate studies at the University of Newcastle, I held a Postdoctoral Fellowship at the University of Basel (Switzerland) from 1990-2. I returned to Australia in 1993 to take up an Australian Research Council Postdoctoral Fellowship at the Australian National University (Canberra) from 1993-4. I joined The University of Queensland in 1994.

Natural Products from Traditional Medicines and drug development.

My group focuses on isolating bioactive natural products from plants and organisms used in traditional and herbal medicines in cultures across the globe. We screen extracts and purified compounds for biological activity and for bioavailability using cell techniques. We are also involved in synthesising analogues of natural compounds and components of subunit vaccines. We also work with first responders to develop methods for detection and decompostion of dangerous chemicals.

Professor Mark Blaskovich is an antibiotic hunter and Director of Translation at the Institute for Molecular Bioscience at The University of Queensland. He is co-founder and former Director of the Centre for Superbug Solutions at IMB.

A medicinal chemist with 15 years of industrial drug development experience prior to his academic career, Mark has been developing new antibiotics to treat drug resistant pathogens and using modified antibiotics to detect bacterial infections. He is a co-founder of the Community for Open Antimicrobial Drug Discovery, a global antibiotic discovery initiative, and has led a number of UQ-industry collaborations focused on antibiotic development. An inventor on eleven patent families, Mark has developed drugs in clinical trials, published more than eighty research articles, and received over $10m in grant funding.

My research group specializes in the detection, isolation, identification and evaluation of biologically active small molecules from Nature (natural products). We acquire valuable knowledge on how and why natural products are made, and apply this knowledge to better understand living systems, and solve important scientific and societal challenges.

To achieve these goals we have established specialist capabilities that extend across;

Microbiology – the isolation, characterization and cultivation of bacterial and fungal strains.

Chemistry – the extraction and fractionation of natural extracts, the purification, chemical and spectroscopic characterization, and structure elucidation of natural products, and the use of synthetic and medicinal chemistry to explore bioactive scaffolds.

Biology – to evaluate extracts and natural products against an array of bioassays, leading to new human pharmaceuticals that target such indications as infectious and neurodegenerative diseases, cancer, pain and epilepsy, as well as new animal health products and new crop protection agents.

Dr Fernanda Cardoso is a Brazil-born Australian researcher interested in venom peptide-based biodiscovery and therapeutics development. Cardoso was awarded an MSc in Molecular Pharmacology and a PhD with an emphasis in Biochemistry and Immunology and is part of the Institute for Molecular Bioscience, where she develops novel therapies for complex neurological diseases. Cardoso has interdisciplinary training in the fields of neuropharmacology, medicinal chemistry and chemical biology and a strong background in drug discovery, which provides the skills to identify naturally occurring or synthetic bioactive molecules and to study their effects in human physiology with applications in neurologic disorders such as chronic pain, irritable bowel syndrome (IBS), and motor neuron disease (MND). Please see Dr Cardoso’s Grants and Publications list for more details.

Before joining the University of Queensland, Dr Cardoso was part of the Queensland Institute for Medical Research, holding a prestigious CAPES Postdoctoral Fellowship. During this period, Cardoso developed unique high-throughput screen platforms for discovering protein and peptide targets of novel therapies to combat infectious diseases and novel helminth-derived bioactives with anti-inflammatory properties. Please see Dr Cardoso’s Publications list for more details.

Dr Cardoso is currently part of the Centre for Drug Discovery and manages several industry and academic projects studying ion channel modulators derived from natural repertoires, particularly venoms, and developing novel, effective drugs to treat neurological disorders.

Keith is Molecular Virologist and group leader with a dual appointment within the Australian Bioengineering and Nanotechnology Institute and the School of Chemistry and Molecular Biosciences. His research is focused on vaccine development and the understanding of medically and environmentally significant viruses. Keith is one of the inventors of a UQ’s molecular clamp platform and is the co-leader of a program to produce a vaccine for COVID-19 at UQ. Keith has played a leading role in designing and implementing an epidemic response vaccine pipeline which enabled the progression of UQ’s COVID-19 vaccine candidate from sequence information to clinical trial dosing within 6 months.

Keith completed his PhD at the University of Queensland in 2007 on the structure and function of flavivirus NS3 protease. Subsequently, he spent three years (2007-2010) as a post-doctoral researcher at one of Spain’s most respected research institutes, Instituto Salud Carlos III, where I conducted research on the fusion protein of Respiratory Syncytial viurs as a target for conformationally specific neutralizing antibodies. Keith returned to UQ in 2011 and his research has focused on understanding of many medically and environmentally important viruses and bacteria, particularly focussing on Influenza, Respiratory Syncytial virus (RSV), SARS-CoV-2, Koala Retrovirus and Streptococcus pneumoniae.

Dr Clark is a Senior Lecturer at the School of Biomedical Sciences where he is Head of the Peptide Chemical Biology Lab. He completed his PhD in 2000 at the UQ Chemistry Department studying marine natural products chemistry and chemical ecology with Prof. Mary Garson. He then shifted his research focus towards peptide chemistry, structural biology and drug design when he was recruited to the lab of Prof. David Craik at the IMB. His current research focus is the development of technologies to stabilise peptide therapeutics and the elucidation of the structure/function activity of bioactive peptides.

During my postgraduate studies and postdoctoral fellowship, I gained experience in a wide range of chemical biology techniques as well as in initiating and managing collaborations. Building on a background in chemistry and biochemistry, I developed my skills in peptide chemistry and NMR spectroscopy during my PhD in Australia, synthesizing a variety of disulfide-rich cyclic peptides and elucidating their structures and dynamics by NMR spectroscopy. I have gained further experience in protein chemistry, solid phase peptide synthesis and protein ligations during my postdoctoral fellowship in Vienna, collaborating with Syntab Therapeutics on a project involving synthesis and development of synthetic antibodies for cancer therapy. I have recently taken up a UQ Development Fellowship to establish my independent research area in synthesis and structural biology of posttranslationally modified proteins.

James De Voss received a B. Sc (Hons) in Chemistry and a University Medal from the University of Queensland in 1984. He was a Royal Commission for the Exhibition of 1851 scholar at Cambridge University, where he worked on the biosynthesis of Vitamin B12 with Prof. Sir Alan Battersby. A postdoctoral fellowship, again from the Royal Commission for the Exhibition of 1851, allowed him to work with Prof. Craig Townsend at Johns Hopkins University on the mechanism of DNA cleavage caused by the enediyne antibiotic calicheamicin. He was then introduced to the cytochromes P450 by Prof. Paul Ortiz de Montellano with whom he worked while at the University of California, San Francisco. Since returning to the University of Queensland to take up an academic appointment, initially as a Senior lecturer and subsequently as a Reader and then a Professor, he has continued his interest in problems at the interface of chemistry and biology and currently works with a range of bacterial, insect and mammalian P450s, as well as on the biogenesis of insect pheromones and phytochemistry of herbal medicines.

I was awarded my PhD in Computational Biophysics from the University of Western Australia (2012) for my work on combining molecular modelling and simulation approaches with fluorescence spectroscopy experiments to study mechanosensitive ion channels.

Following this, I carried out Postdoctoral work at the University of Queensland and Curtin University, funded by Early Career Fellowships from the Swiss National Science Foundation and the Australian National Health and Research Council (NHMRC). In 2019, I joined UTS under a UTS Chancellor's Postdoctoral Research Fellowship and started my independent research group. In 2021, I returned to the University of Queensland as a Senior Lecturer.

Apart from my research, I am a passionate advocate for mental health in academia and

supporting PhD students. My teaching and supervision are guided by encouraging students to become 'critical thinkers'. I practice mindful leadership and aim to integrate kindness and gratitude into how I lead my research team.

Professor Fairlie is an NHMRC Research Investigator Fellow (Level 3) (2022-present), a Node Leader of the ARC Centre of Excellence for Innovations in Peptide Protein Science, one of four Centre Directors and former Head of the Division of Chemistry of Structural Biology at the Institute for Molecular Bioscience (since 2009), and an Affiliate Professor of the School of Chemistry and Molecular Biosciences. He was previously an NHMRC Senior Principal Research Fellow (2012-2021), a Node Leader at the ARC Centre of Excellence in Advanced Molecular Imaging (2014-2021), an ARC Federation Fellow (2006-2011), an ARC Professorial Fellow (2002-2006), and Scientific Director and Chief Scientific Officer of a startup company. He undertook postdoctoral studies at Stanford University and University of Toronto, postgraduate studies at Australian National University and University of New South Wales, and undergraduate studies at University of Adelaide.

His research group works across the disciplines of chemistry (synthesis, structure, reaction mechanisms), biochemistry (enzyme inhibitors, protein-protein interactions, GPCRs, transcription factors), immunology (innate immune cells in health and disease, mucosal T cells), and pharmacology (molecular pharmacology and human cell signalling, experimental pharmacology in rodent models of human diseases). He has published over 480 scientific journal articles in high impact chemistry journals (e.g. Chem Rev, Acc Chem Res, J Am Chem Soc, Angew Chem Int Edit, Chem Sci, J Med Chem, Org Lett, J Org Chem) and biology journals (e.g. Nature, Science, Nat Rev Endocrinol, Mol Cancer, Immunity, Nature Immunology, Science Immunology, Am J Resp Crit Care Med, J Hepatol, Trends Immunol, Mol Neurodegen, Adv Drug Deliv Rev, Nature Communications, Trends Pharmacol Sci, J Exp Med, J Clin Invest, Kidney Int, Arthritis & Rheum, Science Advances, Pharmacol Ther, Cancer Res, Proc Natl Acad Sci USA, Dev Cell, Curr Biol, J Cell Biol, Cell Reports, PloS Biol, Br J Pharmacol, JCI Insight, Diabetes, Mucosal Immunol, etc). He has been a Highly Cited Researcher (Clarivate Analytics), with over 37,000 citations and 113 publications with over 100 citations (Google Scholar), and has collaborated with many of the world’s largest pharmaceutical and biotechnology companies.

Carbohydrate chemistry, medicinal chemistry, drug discovery

Vito Ferro is a Professor in the School of Chemistry & Molecular Biosciences. His research interests are in the area of synthetic carbohydrate chemistry, and drug design and development.

Professor Mary Fletcher is a natural product organic chemist, and led the Natural Toxin group within the Centre for Animal Science, Queensland Alliance for Agricultural and Food Innovation (QAAFI) 2010-2024,before being appointed Emeritus Professor in 2024. She previously worked as a research chemist at both The University Queensland and Queensland Primary Industries (Biosecurity Queensland), before joining the Queensland Alliance for Agricultural and Food Innovation in 2010. Prof Fletcher's current interest focuses on bioactives that reduce enteric methane and the application of slow release delivery systems appropriate to rangeland grazing systems. Prof Fletcher has an industry recognised expertise as an applied organic chemist with a specialist interest in the identification and analysis of natural toxins and other bioactives in a range of plants, fungi and agricultural products. Such toxins and bioactives can affect both human and animal health posing risks to livestock production, food safety and market access.

Prof Fletcher is also an Affiliate Professor in the School of Chemistry and Molecular Biosciences (http://www.scmb.uq.edu.au/index.html), and an Affiliated Scientist at the Biosciences eastern & central Africa-International Livestock Research Institute (BecA-ILRI) Hub in Nairobi, Kenya (http://hub.africabiosciences.org/).

Prof Fletcher is a Fellow of the Royal Australian Chemical Institute and in 2016 was elected President of the Queensland Branch of the Royal Australian Chemical Institute (http://www.raci.org.au/branches/qld-branch).

Venoms play a range of adaptive roles in the animal kingdom from predation to defense to competitor deterrence. Remarkably, despite their biological importance and uniqueness, the evolution of venom systems is poorly understood. New insights into the evolution of venom systems and the importance of the associated toxins cannot be advanced without recognition of the true biochemical, ecological, morphological and pharmacological diversity of venoms and associated venom systems. A major limitation has been the very narrow taxonomical range studied. Entire groups of venomous animals remain virtually unstudied. My research is inherently interdisciplinary, integrating ecological, evolutionary, and functional genomics approaches in order to understand the evolution of venom systems. Studies range from discovering the shock-inducing hypotensive and anticoagulant venom of the iconic Komodo Dragon through to exploring the unique temperature specific adaptations of Antarctic octopus venoms.